New investor files pharma IPR as patent validity challenges look like being an increasing trend in 2016

Another investment group has filed an inter partes review (IPR) against a pharmaceutical patent, joining the small band of investors that have started to pose a significant challenge to leading drugmakers in the US. The IPR was filed just before…

Get unlimited access to all IAM content